Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senl-h19 CAR-T for Relapsed/Refractory B-ALL
NCT04792593Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SenL_19 in acute lymphoblastic leukemia (ALL), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Status: unknown.
02
Drugs
SenL_19
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04792593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792593.